🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "major milestone" in the battle against superbug strains of the infection, according to scientists.

An International Public Health Issue

Cases of gonorrhoea are on the rise around the world, with data suggesting over 82 million infections per year. Especially elevated rates are seen in Africa and countries within the World Health Organization's designated area, which encompasses China and Mongolia to New Zealand. In England, cases have hit a historical peak, while infection numbers across Europe in 2023 were three times higher compared to the rates from 2014.

“The authorization of new treatments for gonorrhoea is an significant and necessary development in the context of growing infection rates, escalating drug resistance and the highly restricted treatment choices currently available.”

Health officials are increasingly worried about the rise in treatment-resistant strains. The WHO has designated it as a "high-priority threat". A tracking program revealed that resistance to primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Therapies Gain Clearance

One new antibiotic, also known as Nuzolvence, was cleared by the American regulatory agency in December for treating gonorrhoea. This infection can lead to major issues, including the inability to conceive. Researchers hope that specific application of this new drug will help hinder the development of resistance.

Gepotidacin, created by the drugmaker GlaxoSmithKline, also received approval in close succession. This drug, which is additionally indicated for urinary tract infections, was proven in research to be able to combat superbug versions of the gonorrhoea bacteria.

A Novel Partnership

This new treatment emerged from a new, not-for-profit approach for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to see it through.

“This approval marks a major breakthrough in the therapy of superbug gonorrhoea, which until now has been outpacing antibiotic development.”

Research Study Results and Global Access

Based on findings detailed in a major medical journal, the new drug cured the vast majority of cases of the STI. This establishes an comparable level with the typical regimen, which involves an injection and a pill. The study enrolled over 900 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, GARDP has the authority to register and commercialise the drug in many regions with limited resources.

Clinicians treating patients have voiced hope. Having a one-pill regimen like this is seen as a "critical tool" for gonorrhoea control. This is deemed essential to lessen the impact of the illness for people and to halt the transmission of untreatable gonorrhoea around the world.